Search company, investor...

Predict your next investment

Private Equity
dyeecapital.com

Investments

53

Portfolio Exits

3

About DYEE Capital

DYEE Capital is a private equity & venture capital firm.

Headquarters Location

Xiamen, Fujian,

China

+86 0592-2518818

Want to inform investors similar to DYEE Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest DYEE Capital News

InventisBio Raises $147M in Series D Financing

Sep 29, 2020

InventisBio , a Shangai, China-based clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, closed a $147m series D financing. The was led by Hillhouse affiliate GL Ventures, followed by Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital and other investors. The existing shareholders including Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, AdvanTech Capital, and CMB International continued their support. Led by Dr. Yaolin Wang, Chairman and CEO, InventisBio is an innovative biotech company that focuses on the research and development of proprietary small molecule drugs for the treatment of cancer and metabolic diseases. Currently, InventisBio has three drug products in the mid- to late-stage clinical development, and one new product just entered global phase I clinical study. Among them, D-0502 is an oral selective estrogen receptor degrader (SERD), which also acts as an estrogen receptor antagonist, with therapeutic potential for the treatment of hormone receptor positive breast cancer. In addition, the company has independently developed a third-generation EGFR-T790M tyrosine kinase inhibitor BPI-D0316 and out-licensed China right to Betta Pharma. This product is currently in registration trials of first- and second-line treatment of EGFR-mutated non-small cell lung cancer patients and the trials are progressing fast. Funds raised in this round will be mainly used to support the company’s current products into phase II clinical studies in China and the United States, including D-0502 trials in hormone receptor positive breast cancer and D-0120 trials in gout. This round will also support the company’s global clinical development of other new drugs, enable further expansion of the company’s product pipeline and team. FinSMEs 29/09/2020

DYEE Capital Investments

53 Investments

DYEE Capital has made 53 investments. Their latest investment was in Genepoint Biological Technology as part of their Series D on January 1, 2023.

CBI Logo

DYEE Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/18/2023

Series D

Genepoint Biological Technology

$29.6M

No

2

11/4/2022

Series D

Welion

$206.1M

Yes

6

10/20/2022

Series C - II

MaxiNovel

$13.86M

No

4

8/5/2022

Series B

Subscribe to see more

Subscribe to see more

10

7/27/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/18/2023

11/4/2022

10/20/2022

8/5/2022

7/27/2022

Round

Series D

Series D

Series C - II

Series B

Series B

Company

Genepoint Biological Technology

Welion

MaxiNovel

Subscribe to see more

Subscribe to see more

Amount

$29.6M

$206.1M

$13.86M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

6

4

10

10

DYEE Capital Portfolio Exits

3 Portfolio Exits

DYEE Capital has 3 portfolio exits. Their latest portfolio exit was InventisBio on July 25, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/25/2022

IPO

$99M

Public

1

12/2/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/23/2017

Take Private

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/25/2022

12/2/2020

10/23/2017

Exit

IPO

IPO

Take Private

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

10

10

DYEE Capital Team

1 Team Member

DYEE Capital has 1 team member, including current Managing Director, Dezhen Zhu.

Name

Work History

Title

Status

Dezhen Zhu

Managing Director

Current

Name

Dezhen Zhu

Work History

Title

Managing Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.